{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"15"}],"units":"Participants"}],"description":"The objective response rate (ORR) is defined as confirmed complete response or partial response using modified Response Evaluation Criteria in Solid Tumors \\[RECIST\\]: a complete response is the disappearance of all target lesions; a partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","groups":[{"description":"AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG000","title":"Part 1 Cohort 1"},{"description":"AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG001","title":"Part 1 Cohort 2"},{"description":"AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG002","title":"Part 1 Cohort 3"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Non-squamous NSCLC","id":"OG003","title":"Part 2 Cohort 1"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Squamous Non -Small Cell Lung Cancer (NSCLC)","id":"OG004","title":"Part 2 Cohort 2"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Colorectal Cancer (CRC)","id":"OG005","title":"Part 2 Cohort 3"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Pancreatic Cancer","id":"OG006","title":"Part 2 Cohort 4"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Ovarian Cancer","id":"OG007","title":"Part 2 Cohort 5"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Sarcoma","id":"OG008","title":"Part 2 Cohort 6"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"A subject was included in the analysis if they received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Time from first dose up to 24 months","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}